Cellular and T cell engager Immunotherapy

P-002: Ide-cel real-world (RW) and clinical trial long-term safety experience: a special focus on movement and neurocognitive treatment adverse events (MNT AEs) and second primary malignancies (SPMs)

P-004: Association Between Risk Factors and Outcomes Following Fully Human Anti-BCMA CAR-T Progression in Patients with Relapsed/Refractory Multiple Myeloma

P-005: Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

P-007: Absolute lymphocyte count at Day 30 (not earlier) and early CRS predict delayed responses to teclistamab: Results from the US Myeloma Immunotherapy Consortium

P-008: A rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; insights from a multicenter case series.

P-009: Digital Remote Patient Monitoring for Cytokine Release Syndrome in ABBV-383 Treatment: Methodology and Setup

P-010: Efficacy/Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

P-011: Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma

P-012: Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma

P-013: CERVINO: A phase 3, multicenter, randomized, open-label study of ABBV-383 compared with standard available therapies in patients with relapsed or refractory multiple myeloma (RRMM)

P-014: Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial

P-015: RESPONSE OF CD8+ T LYMPHOCYTES UNDER STIMULATION OF DENDRITIC CELLS FUSED WITH MULTIPLE MYELOMA PLASMA CELLS

P-016: Comparative Efficacy of CARVYKTI in CARTITUDE-4 versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

P-018: Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

P-020: Treatment Positioning Model to Evaluate the Survival Benefit of Ciltacabtagene Autoleucel in Second-Line Compared With Later-Line Treatment of Lenalidomide-Refractory Multiple Myeloma

P-021: A German multicenter real-world analysis of talquetamab in 102 patients with relapsed/refractory multiple myeloma

P-024: Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma

P-028: Characteristics of Bridging Therapy and Impact of Pre-lymphodepletion Tumor Burden on Clinical Outcomes of Idecabtagene Vicleucel

P-029: Pharmacokinetics (PK) and immunogenicity of linvoseltamab in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in LINKER-MM1

P-030: Low infection rates in patients (pts) with relapsed/refractory myeloma (RRMM) treated with alnuctamab (ALNUC) in a setting of infection reduction strategies (IRS) and less frequent dosing

P-033: External control analysis for KarMMa-3: idecabtagene vicleucel (ide-cel) vs real-world standard of care (RW SoC; Connect MM) for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

P-036: BCMA after GPRC5D: Efficacy of BCMA-directed therapy on patients with relapsed/refractory multiple myeloma (RRMM) progressing after GPRC5D-directed therapy

P-039: CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

P-042: SWASTH: Phase 1/2 Study of Ribrecabtagene Autoleucel, a BCMA–Directed CAR-T Cell Therapy, in Relapsed-Refractory Multiple Myeloma

P-043: Stem Cell Boost for Persistent Cytopenias After BCMA-Directed Chimeric Antigen Receptor (CAR)-T Cell Therapy

P-044: External control analysis for KarMMa-3: idecabtagene vicleucel (ide-cel) vs real-world standard of care (RW SoC; COTA) for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

P-045: Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMA-2 cohort 2B

P-048: Barriers to the Implementation of Bispecific Antibodies for patient with Relapsed and Refractory Myeloma in the UK: Results of a National Survey

P-049: Teclistamab in real life : Can we shorten the ramp-up ?

P-050: Talquetamab vs Real-World Physician’s Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent

P-052: Efficacy and safety of ide-cel with lenalidomide (R) maintenance versus R maintenance alone in adult patients (pts) with NDMM who have suboptimal response to ASCT: phase 3 KarMMa-9 trial

P-053: Early Absolute Lymphocyte Count after BCMA CAR-T as a Surrogate for CAR-T expansion, response, and Progression Free Survival in Multiple Myeloma

P-057: Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis

P-058: Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

P-062: QUINTESSENTIAL: a multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma

P-063: Systematic literature review and meta-analysis of clinical trials of fourth line or higher treatment for relapsed/refractory multiple myeloma patients

P-064: Trial in Progress: A Retrospective Multi-Country Study of Clinical Outcomes in Patients with R/R Multiple Myeloma Treated with Teclistamab Outside of Clinical Trials

P-066: Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN)

P-067: Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma

P-069: Idecabtagene vicleucel (ide-cel) in patients (pts) with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): the 5-year follow-up analysis from KarMMa

P-070: Safety Profiles of Novel Myeloma Therapies: A Comprehensive FAERS Analysis (Q1 2020 - Q1 2024)

P-071: Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium

P-072: Health Care Resource Utilization and Economic Burden of Cytokine Release Syndrome Management in Patients With Multiple Myeloma Receiving CAR-T Cell and Bispecific Antibody Therapies

P-074: Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma

P-077: Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study

P-078: Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma – Another bridging therapy

P-079: Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

P-081: TALQUETAMAB, A GPRC5DXCD3 BISPECIFIC ANTIBODY, FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN PATIENTS WITH PRIOR EXPOSURE TO BCMA TARGETED THERAPIES - A “REAL WORLD” STUDY

P-082: Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functionally High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis

P-084: Efficacy of linvoseltamab in prespecified high risk subgroups of patients with relapsed/refractory multiple myeloma: Results from LINKER-MM1

P-085: Overcoming Challenges: Development of Two Potent, Domestic BCMA-targeted CAR-T Cell Products for the Treatment of Multiple Myeloma in Brazil

P-086: Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma

P-087: Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience

P-088: Evaluating T-cell fitness pre B-cell maturation antigen (BCMA)-targeted T-cell redirection therapies (TRT) as a predictive marker for efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM)

P-089: Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma

P-090: Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) and 1–3 Prior Lines

P-091: Talquetamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison.

P-092: Monitoring of anti-BCMA CAR-T cells and non-CAR-T immune subsets in multiple myeloma patients

P-093: Real World Data on Bispecific Antibodies in the Brazilian Setting

P-094: The Optimal Lymphodepletion Prior to Eque-cel in Patients with Refractory Relapsed Multiple Myeloma in FUMANBA-1 Study

P-096: Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy

P-098: Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

P-099: Updated Comparative Effectiveness of Talquetamab vs Real-world Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

P-100: Outcomes of R/R MM Patients with Renal Function Impairment Treated with Eque-cel in the Pivotal Phase 2 FUMANBA-1 Study